Brief: Shionogi: Signed Sub-Licensing Agreement With JEIL Pharmaceutical For Development And Sale Of Drug That Treats Infections Caused By Antimicrobial Resistance
28/07/2022 02:51
July 28 (Reuters) -
* SHIONOGI: SIGNED SUB-LICENSING AGREEMENT WITH JEIL
PHARMACEUTICAL FOR DEVELOPMENT AND SALE OF DRUG THAT TREATS
INFECTIONS CAUSED BY ANTIMICROBIAL RESISTANCE
Further company coverage: [ 4507.T 271980.KS ]
(Reporting by Sakura Murakami)
((Sakura.Murakami@thomsonreuters.com;))
Recent news on Jeil Pharmaceutical
See all newsBrief: Shionogi: Signed Sub-Licensing Agreement With JEIL Pharmaceutical For Development And Sale Of Drug That Treats Infections Caused By Antimicrobial Resistance
Rockwell Medical surges as partner gets S.Korea approval for Triferic injection
Rockwell Medical Inc: Rises on license deal with South Korean firm
Brief: Jeil Pharma Holdings buys 13.53 pct stake in Jeil Pharmaceutical